Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Xalkori | Crizotinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xalkori | Crizotinib | First Line ALK Positive Advanced NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
Wegovy | semaglutide | Weight management | Do not reimburse | Complete |